Dr.Β SagarΒ Lonial
MD, FACP, FASCO
Chief Medical Officer & Professor, Hematology-Oncology
corporate_fareWinship Cancer Institute of Emory University, Atlanta
Sagar Lonial
MD, FACP, FASCO
Dr. Sagar Lonial is an internationally recognised hematologist-oncologist and one of the world's leading authorities on multiple myeloma and plasma cell disorders. He serves as Chief Medical Officer at Winship Cancer Institute of Emory University and as Professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, United States.
Dr. Lonial completed his medical degree at the University of Louisville School of Medicine in 1993, followed by residency training at Baylor College of Medicine and a hematology-oncology fellowship at Emory University School of Medicine, where he has practised since 2000. He holds the Anne and Bernard Gray Family Chair in Cancer and is board-certified in both hematology and medical oncology by the American Board of Internal Medicine. With more than 25 years of specialist clinical practice and over 400 peer-reviewed publications, his work has helped shape modern treatment standards for multiple myeloma across newly diagnosed, relapsed, and refractory disease settings. In 2025, the International Myeloma Foundation honoured him with the Robert A. Kyle Lifetime Achievement Award for his career-long contributions to advancing myeloma research and treatment.
CancerFax can coordinate medical-report review, second-opinion consultation, and case submission support for international patients seeking Dr. Lonial's expertise at Winship Cancer Institute.
Why Consider Dr. Sagar Lonial?
Dr. Lonial is one of the most widely cited myeloma specialists in the United States, combining deep clinical expertise with active research leadership at a top-ranked academic cancer centre.
Areas of Specialisation
Focused clinical expertise in multiple myeloma and plasma cell disorders
Dr. Lonial's clinical practice is centred on multiple myeloma across all disease stages, from newly diagnosed to relapsed and refractory settings. His expertise encompasses bone marrow transplantation, cellular therapies, and novel-agent combinations that have transformed modern myeloma care.
Multiple Myeloma Treatment
Comprehensive management of newly diagnosed, relapsed, and refractory multiple myeloma using evidence-based and novel treatment combinations.
- arrow_rightInduction therapy planning with novel-agent triplet and quadruplet regimens
- arrow_rightTransplant eligibility assessment and pre-transplant optimisation
- arrow_rightRisk stratification and molecular profiling to guide treatment intensity
- arrow_rightSalvage therapy selection based on prior lines and disease biology
- arrow_rightBispecific antibody therapy in eligible relapsed/refractory patients
- arrow_rightAntibody-drug conjugate approaches including belantamab mafodotin strategies
- arrow_rightClinical trial access for patients with limited prior-approved options
Cellular Therapies & Bone Marrow Transplantation
Advanced cellular therapy approaches including CAR T-cell therapy and autologous stem cell transplantation as part of integrated myeloma care.
- arrow_rightBCMA-directed CAR T-cell therapy evaluation and referral for eligible patients
- arrow_rightPost-CAR T monitoring and management of treatment-related effects
- arrow_rightAutologous stem cell transplantation as part of myeloma induction-consolidation strategy
- arrow_rightMaintenance therapy planning following autologous transplant, including clinical trial options
- arrow_rightPost-transplant immune recovery assessment and monitoring
Immunotherapy & Targeted Approaches
Immunotherapy and molecularly targeted strategies for plasma cell disorders and selected haematologic malignancies.
- arrow_rightMonoclonal antibody therapy including anti-CD38 agents (daratumumab, isatuximab)
- arrow_rightElotuzumab-based combination regimens for SLAMF7-expressing myeloma
- arrow_rightImmune microenvironment research informing novel treatment combinations
- arrow_rightTalquetamab and teclistamab for relapsed/refractory myeloma
- arrow_rightClinical trial access for emerging bispecific antibody combinations
Procedures & Clinical Services
Specialist myeloma care from diagnosis through advanced cellular therapy
Dr. Lonial's clinical services span the full spectrum of multiple myeloma management, including systemic therapy, transplantation, CAR T-cell therapy, clinical trial access, and second-opinion evaluation.
Systemic Myeloma Therapy
Medical OncologyInduction, consolidation, and maintenance treatment planning for multiple myeloma across all disease stages.
Bone Marrow & Cellular Transplantation
TransplantAutologous stem cell transplant and advanced cellular therapies as part of comprehensive myeloma care at Winship Cancer Institute.
Targeted & Bispecific Antibody Therapy
Targeted TherapyNovel targeted and immunological approaches for relapsed and refractory multiple myeloma.
Clinical Trial Access
Complex DiseaseActive participation in myeloma clinical trials, offering eligible patients access to investigational therapies at Winship Cancer Institute.
Second Opinion Consultations
Second OpinionIndependent expert review of myeloma diagnosis, staging, and treatment planning by a recognised international specialist.
Disease Monitoring & Multidisciplinary Care
MonitoringOngoing surveillance and coordinated multidisciplinary management for patients with multiple myeloma.
Research & Publications
Over 400 peer-reviewed publications and active clinical trial leadership in multiple myeloma
Dr. Lonial is one of the most prolific academic physicians in myeloma research. His work spans immunotherapy, post-transplant immune recovery, novel targeted agents, bispecific antibodies, CAR T-cell therapy evolution, and combination strategies in both myeloma and lymphoma. He holds editorial roles at the Journal of Clinical Oncology, Leukemia, Clinical Lymphoma Myeloma and Leukemia, SOHO Insider, and Cancer, and has served as an invited reviewer for Blood, Haematologica, Clinical Cancer Research, and The New England Journal of Medicine.
Dr. Lonial leads active myeloma clinical trials at Winship Cancer Institute. CancerFax can coordinate case review and trial eligibility assessment for international patients.
Education & Training
Dr. Lonial completed his medical training at the University of Louisville, followed by residency at Baylor College of Medicine, and a specialist fellowship in hematology-oncology at Emory University School of Medicine, where he has practised since 2000.
Clinical Experience
Dr. Lonial has practised hematology-oncology at Winship Cancer Institute of Emory University since completing his fellowship in 2000, rising to the institution's most senior clinical and academic leadership roles.
Languages & International
Dr. Lonial consults in the following language.
CancerFax coordinates certified medical interpreters for international patients requiring consultation support in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Lonial.
How CancerFax Helps You Access Dr. Sagar Lonial
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Sagar Lonial's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Sagar Lonial's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Sagar Lonial before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Sagar Lonial's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Sagar Lonial's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Sagar Lonial's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Sagar Lonial
Dr. Lonial specialises in multiple myeloma and plasma cell disorders. Winship Cancer Institute lists his specialty as Myeloma and Plasma Cell Disorders. He treats patients across all disease stages β newly diagnosed, relapsed, and refractory β and is involved in CAR T-cell therapy, autologous stem cell transplantation, and clinical trials for myeloma.
Dr. Lonial practises at Winship Cancer Institute of Emory University and Emory University Hospital in Atlanta, United States. He serves as Chief Medical Officer of Winship Cancer Institute and Professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare the case summary, and coordinate the next steps with the Winship Cancer Institute team, subject to availability and case acceptance.
Dr. Lonial practises at Winship Cancer Institute in Atlanta, and Emory Healthcare lists telehealth visits as available through his provider profile. CancerFax can coordinate report review, second-opinion consultation, and case submission support for international patients. Travel, appointment logistics, and teleconsultation availability should be confirmed with the institution or the CancerFax team before scheduling.
Yes. A second-opinion request can be submitted through CancerFax with the patient's bone marrow biopsy and pathology reports, cytogenetics, serum protein electrophoresis results, imaging, and prior treatment history. Dr. Lonial can provide an independent specialist assessment of diagnosis, risk stratification, and treatment options. The consultation format and availability are subject to institutional scheduling.
Yes. Dr. Lonial is a lead member of the clinical trials team at Winship Cancer Institute. Active trials on his profile include studies on iberdomide maintenance after autologous stem cell transplant, talquetamab in relapsed/refractory myeloma, and MMSET inhibition in multiple myeloma. CancerFax can help assess trial eligibility and coordinate the enquiry process.
Connect with Sagar Lonial Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.